RecruitingNot ApplicableNCT03487185

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy


Sponsor

The George Washington University Biostatistics Center

Enrollment

1,500 participants

Start Date

Aug 3, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Singleton gestation. Twin gestation reduced to singleton, either spontaneously or therapeutically, is not eligible unless the reduction occurred before 14 weeks project gestational age.
  • Gestational age at randomization between 14 weeks 0 days and 21 weeks 6 days based on clinical information and evaluation of the earliest ultrasound.
  • Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and \<30.

Exclusion Criteria19

  • Previously prescribed, current or planned therapy for sleep apnea.
  • Age \< 18 years, because the rate of sleep apnea in this population is extremely low.
  • Inability to sleep in a stable place with access to the CPAP machine at least 5 nights per week.
  • Asthma requiring systemic steroid therapy for more than 14 days within the past 6 months because this population is expected to be unresponsive to CPAP therapy.
  • Current use of prescribed sleeping pills for insomnia.
  • Chronic medical conditions requiring oxygen supplementation (e.g. pulmonary fibrosis, pulmonary hypertension, cystic fibrosis) because this population is expected to be unresponsive to CPAP therapy.
  • Chronic renal disease with serum creatinine \>1.3 mg/dL because the primary outcome would be pre-determined.
  • Antiphospholipid antibody syndrome, because it would compromise the primary outcome diagnosis.
  • History of medical complications such as:
  • Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes)
  • Thrombocytopenia with platelet count \<100,000 because of the difficulty in assessing the primary outcome.
  • Active vaginal bleeding (more than spotting) at the time of randomization.
  • Known chromosomal, genetic, major malformations or fetal demise, or planned termination of pregnancy because inclusion would compromise evaluation of secondary neonatal outcomes.
  • Known major uterine malformations associated with adverse pregnancy outcomes.
  • Current use of opiates (heroin, methadone, or other daily opioid use) due to inaccuracy of the home sleep test and inefficiency of CPAP.
  • Active drug use, alcohol use, or unstable psychiatric condition.
  • Participation in another interventional study that influences preeclampsia, hypertensive disorders of pregnancy, or GDM.
  • Prenatal care or delivery planned at a non-network center where access to the complete electronic medical record will not be available to research staff.
  • Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.

Interventions

DEVICEContinuous Positive Airway Pressure

Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling

OTHERSleep Advice Control

Initial sleep advice counseling alone


Locations(14)

University of Alabama - Birmingham

Birmingham, Alabama, United States

Regents of the University of California San Francisco

San Francisco, California, United States

Northwestern University

Chicago, Illinois, United States

Columbia University

New York, New York, United States

University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, United States

Case Western Reserve-Metro Health

Cleveland, Ohio, United States

Ohio State University Hospital

Columbus, Ohio, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Magee Women's Hospital of UPMC

Pittsburgh, Pennsylvania, United States

Brown Univeristy

Providence, Rhode Island, United States

University of Texas Medical Branch

Galveston, Texas, United States

Baylor College of Medicine

Houston, Texas, United States

University of Texas - Houston

Houston, Texas, United States

University of Utah Medical Center

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03487185


Related Trials